Garber Alan M 4

What Happened

• Alan M. Garber, a director of Vertex Pharmaceuticals (VRTX), was granted 31.56 deferred stock units on 2026-07-15. The units are valued at $475.28 each, for a total grant value of $15,000. This transaction is coded as an award/acquisition (derivative), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-07-15; Form 4 filed: 2026-07-17 (timely filing).
• Grant: 31.56 deferred stock units at $475.28 per unit; total value $15,000.
• Shares owned after transaction: not specified in the filing.
• Footnote: Each deferred stock unit equals one share of common stock and will be paid out in common stock upon the earliest of (i) termination of Dr. Garber’s board service, (ii) a change of control, or (iii) Dr. Garber’s disability or death.
• Transaction type: Award/derivative (code A) — not a purchase (P) or sale (S).

Context

• Deferred stock units are a common form of director compensation and represent a future right to receive shares rather than an immediate market purchase. Such awards do not by themselves indicate the insider’s view on the company’s stock price; they reflect compensation terms and vesting/settlement conditions.